©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Substrate Specificities of the Insulin and Insulin-like Growth Factor 1 Receptor Tyrosine Kinase Catalytic Domains (*)

(Received for publication, August 18, 1995)

Bin Xu Vincent G. Bird W. Todd Miller (§)

From the Department of Physiology and Biophysics, School of Medicine, State University of New York, Stony Brook, New York 11794

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

To compare the substrate specificities of the insulin and insulin-like growth factor 1 (IGF-1) receptor tyrosine kinases, the catalytic domains of the enzymes have been expressed in Escherichia coli as fusion proteins. The purified proteins have kinase activity, demonstrating that the catalytic domain of IGF-1 receptor, like that of insulin receptor, is active independent of its ligand-binding and transmembrane domains. The specificities of the two enzymes for the divalent cations Mg and Mn are indistinguishable. A series of peptides has been prepared that reproduces the major phosphorylation sites of insulin receptor substrate-1, a common substrate for the two receptor tyrosine kinases in vivo. Insulin and IGF-1 receptors show distinct preferences for these peptides; whereas insulin receptor prefers peptides based on Tyr-987 or Tyr-727 of insulin receptor substrate-1, the IGF-1 receptor preferentially recognizes the Tyr-895 site. The latter site, when phosphorylated, is a binding site for the SH2 domain-containing adapter protein Grb2. The ability of the two receptor tyrosine kinases to be phosphorylated and activated by v-Src has also been examined. The catalytic activity of IGF-1 receptor is stimulated approx3.4-fold by treatment with purified v-Src, while insulin receptor shows very little effect of Src phosphorylation under these conditions. This observation is relevant to recent findings of IGF-1 receptor activation in Src-transformed cells, and may represent one method by which Src amplifies its mitogenic signal. Collectively the data suggest that the catalytic domains of the two receptor kinases possess inherently different substrate specificities and signaling potentials.


INTRODUCTION

The polypeptide hormones insulin and insulin-like growth factor 1 (IGF-1) (^1)are closely related growth factors that regulate cell growth and metabolism. The two growth factors produce their biological effects by binding to distinct receptors on the surface of target cells. Although insulin and IGF-1 receptors (IR and IGF-1R, respectively) have some functions in common, recent evidence suggests that the receptors play significantly different biological roles (for review, see Kahn(1985), Rechler and Nissey(1990), and Adamo et al.(1992)). While insulin primarily stimulates physiological processes such as glucose transport and biosynthesis of glycogen and fat (Kahn, 1985), IGF-1 has been shown to be more potent in stimulating cell growth by increasing DNA synthesis, and in promoting cell differentiation (Lammers et al., 1989; Rechler and Nissey, 1990). In keeping with its mitogenic role, IGF-1R has been shown to be important in the onset and maintenance of the transformed phenotype in vivo and in vitro (Kaleko et al., 1990; Baserga, 1995).

The receptors for the two growth factors are highly homologous. They share the same oligomeric structure: in each case the receptor is made up of two extracellular alpha subunits containing the ligand-binding domain and two transmembrane beta subunits possessing tyrosine kinase activity (Yarden and Ullrich, 1988). The tyrosine kinase catalytic domains of the insulin and IGF-1 receptors, located in the cytoplasmic portions of the beta subunits, possess approx84% sequence identity (Ullrich et al., 1986). The positions of N-linked glycosylation sites and cysteine residues in the extracellular domains are also highly conserved. Activation of the receptors is thought to occur in a similar manner. Binding of ligand to the alpha subunits activates IR or IGF-1R, leading to autophosphorylation of tyrosine residues in the beta subunits (Yarden and Ullrich, 1988). Signaling via the IR and IGF-1R has been demonstrated to be dependent on their tyrosine kinase domains (Ebina et al., 1987; Chou et al., 1987; Kato et al., 1993), which catalyze the phosphorylation of specific substrates, including the 185-kDa insulin receptor substrate-1 (IRS-1) protein (Sun et al., 1991). IRS-1 is a major substrate for both IR and IGF-1R in vivo (Sun et al., 1991; Myers et al., 1993), and it serves as an intermediate docking protein, providing binding sites for multiple downstream SH2 domain-containing proteins. For example, after IR and IGF-1R activation, the tyrosine-phosphorylated form of IRS-1 binds to the 85-kDa regulatory subunit of the phosphatidylinositol 3-kinase, and this interaction activates phosphatidylinositol 3-kinase (Backer et al., 1992; Giorgetti et al., 1993; Myers et al., 1993). In addition to phosphatidylinositol 3-kinase, IRS-1 can also interact with the growth factor receptor bound-2 (Grb2) protein and the SH2 containing tyrosine phosphatase Syp, in each case by SH2 domains in the downstream proteins binding to phosphorylated tyrosine residues within IRS-1 (Sun et al., 1993). Thus, insulin and IGF-1 appear to activate at least one common signaling pathway through IRS-1 phosphorylation and phosphatidylinositol 3-kinase activation. On the other hand, because the binding of insulin and IGF-1 to their respective receptors trigger distinct cellular responses, the signaling pathways emanating from the receptors are presumably different from each other, at least in part. At present the molecular basis for these differences in signal transduction remain unclear, particularly in light of the structural homology of the receptors. Effects specific for IGF-1 may be mediated by additional substrates that have not yet been identified, or by differential phosphorylation of sites on known substrates such as IRS-1.

Some experimental systems for comparing the activities of IR and IGF-1R have been described. Using highly purified preparations of IGF-1R and IR from human placenta, Sahal et al.(1988) demonstrated intrinsic differences in substrate specificity between the two kinases toward polymeric substrates. Although (Glu^4,Tyr^1) and (Glu^6,Ala^3,Tyr^1)served as substrates for both tyrosine kinases, IGF-1R phosphorylated the former polymer approximately four times more efficiently than the latter polymer. In contrast, insulin receptor phosphorylated the two polymeric substrates nearly equally. In addition, insulin receptor was at least 10-fold more sensitive to inhibition by polymers such as (Tyr,Ala,Glu) and (Tyr-Ala-Glu) than the IGF-1 receptor. The signaling potentials of insulin and IGF-1 receptors have also been compared in studies using chimeric receptors. A receptor consisting of the ligand-binding domain of IR and the cytoplasmic domain of IGF-1R is 10 times more active in stimulating DNA synthesis than the IR itself (Lammers et al., 1989), suggesting that dissection of the substrate specificities of IR and IGF-1R is possible. We hypothesize that a difference in substrate specificity between the two catalytic domains allows IGF-1R to transmit signals which are distinct from those mediated by IR. The experiments described in this paper attempt to identify ``downstream'' events which are specific for IGF-1 through an examination of substrate recognition by the IGF-1 receptor.


EXPERIMENTAL PROCEDURES

Materials

Ex-cell 401 Media was from JRH Biosciences and antibiotic/antimycotic and fetal bovine serum were from Life Technologies, Inc. Glutathione-agarose was from Molecular Probes, Inc. Phosphocellulose P81 paper was obtained from Whatman. [-P]ATP was from Amersham, and Centricon-30 concentrators were purchased from Amicon. Peptides were prepared using standard solid-phase methodology with a t-butoxycarbonyl protection strategy (Stewart and Young, 1984). Side chain deprotection and cleavage from the solid-phase support were accomplished using a Depro peptide deprotection kit (Sigma). Peptides were purified by semipreparative high performance liquid chromatography on a Vydac C18 column with a mobile phase composed of acetonitrile in 0.05% trifluoroacetic acid, and were characterized by amino acid analysis and mass spectrometry. Expression of the 60-kDa Rous sarcoma virus v-src gene product for these studies was carried out in Sf9 cells infected with a recombinant baculovirus harboring the v-src gene (Garcia et al., 1993). Immunoaffinity purification of v-Src was performed as described previously (Garcia et al., 1993).

Expression of Human IGF-1R and IR Catalytic Domains

The catalytic domains of IGF-1 and insulin receptors were expressed in Escherichia coli as GST fusion proteins. The expression vectors were assembled from polymerase chain reaction-amplified fragments of the catalytic domains from cDNAs provided by Dr. Jonathan Whittaker, Div. of Endocrinology, SUNY at Stony Brook School of Medicine. For these experiments, the portion of tyrosine kinase sequences included is the region of high homology among all kinase catalytic domains (corresponding to residues 40-300 of the cAMP-dependent protein kinase) (Hanks et al., 1988). Pairs of oligonucleotides corresponding to the borders of catalytic domain sequences of insulin and IGF-1 receptors were used as polymerase chain reaction primers.

The polymerase chain reaction primers had 25 nucleotides of complementarity with the template and encoded unique restriction sites (BamHI at the 5` end and EcoRI at the 3` end). Amplified fragments consisted of the following regions: for the IGF-1R kinase domain, amino acids 956 to 1246; for the IR kinase domain, amino acids 971 to 1262. Polymerase chain reaction products were digested with BamHI and EcoRI, purified from agarose gels, and subcloned into the EcoRI-BamHI sites of the expression vector pGEX 2T. The DNA sequences of the inserted regions were determined using the Sequenase kit (U. S. Biochemical Corp.).

Expression of the GST fusion proteins was carried out in bacterial strain NB42 as described previously (Smith and Johnson, 1988; Garcia et al., 1993), with the following modifications. Overnight cultures (50 ml) of E. coli strain NB42 harboring each plasmid were inoculated into 1 liter of LB broth containing ampicillin (50 µg/ml). The cultures were incubated for 2 h at 37 °C, at which time isopropyl beta-D-thiogalactopyranoside was added to a final concentration of 0.2 mM. The cultures were grown for an additional 5 h at 30 °C. E. coli cells expressing the GST fusion proteins were lysed in a French pressure cell. After centrifugation of the cell lysates (13,000 times g, 30 min), cell pellets were resuspended in 1.5% N-lauroylsarcosine (Sigma), 25 mM triethanolamine, 1 mM EDTA, pH 8.0. This mixture was rocked at 4 °C for 30 min, then recentrifuged at 4 °C (10,000 times g, 10 min). This supernatant was combined with that from the initial centrifugation and applied to glutathione-agarose (Molecular Probes, Inc.). After washing with 50 mM HEPES (pH 7.4), 100 mM EDTA, purification of the IR and IGF-1R constructs was carried out by elution with excess reduced glutathione (Smith and Johnson, 1988). In both cases, purification of the fusion proteins on glutathione-agarose yielded proteins which were >95% pure, as judged by SDS-polyacrylamide gel electrophoresis with Coomassie Blue staining. Proteins were stored in 40% glycerol at -20 °C. After purification, tyrosine kinase activity was demonstrated toward synthetic peptides using the phosphocellulose paper assay (Casnellie, 1991).

Kinetics of Peptide Phosphorylation

Phosphorylation assays were carried out in total volumes of 25 µl at 30 °C. Each reaction contained 50 mM Tris-HCl (pH 7.4), 10 mM MgCl(2), and 2 mM MnCl(2) (except as noted), 1 mg/ml bovine serum albumin, and 200 µM [-P]ATP (100-500 cpm/pmol), with varying peptide concentrations. Reactions were initiated by the addition of 5 µl of GST-IR or GST-IGF-1R fusion protein (0.5 µg) and were terminated by the addition of 45 µl of cold 10% trichloroacetic acid. The reaction mixtures were centrifuged for 2 min in an Eppendorf microcentrifuge and 35 µl of the supernatants were spotted onto 2.1-cm diameter phosphocellulose paper circles, as described (Casnellie, 1991). The phosphocellulose pads were washed three times with cold 0.5% phosphoric acid and once with acetone, dried, and counted dry in a liquid scintillation counter to measure incorporation of P into peptide. Initial rates of reaction (5%) were measured in triplicate and kinetic constants were determined by weighted nonlinear least-squares fit to the hyperbolic velocity versus [substrate] plots using the iterative program NFIT (Island Products, Galveston, TX).

Phosphorylation by v-Src

GST fusions of IGF-1 or insulin receptor (2 µg) were incubated with purified v-Src (6 µg) in 50 mM Tris-HCl (pH 7.4), 10 mM MgCl(2), 1 mg/ml bovine serum albumin, and 200 µM unlabeled ATP for 20 min at 30 °C. The GST fusions were reisolated by rocking with 50 µl of a 1:2 slurry of glutathione-agarose for 25 min at 4 °C. The glutathione-agarose beads were collected by brief centrifugation and washed with 500 µl of cold 50 mM Tris (pH 7.4). After centrifugation, the resin-bound receptor kinases were incubated with 800 µM Peptide Y727 and 200 µM [-P]ATP under the conditions described above for peptide kinetic measurements. Reactions proceeded for 20 min and were analyzed using the phosphocellulose paper assay (in this case, trichloroacetic acid was not added; reactions were terminated by centrifugation to remove kinases bound to glutathione-agarose). In some experiments v-Src was added together with 1 µg of Yersinia tyrosine phosphatase Yop51*Delta162 (Zhang et al., 1992) (kind gift of Dr. Zhong-Yin Zhang, Albert Einstein College of Medicine). The tyrosine phosphatase was not a GST fusion protein and consequently it was removed when the receptor tyrosine kinases were adsorbed onto glutathione-agarose.


RESULTS

Expression of Human IGF-1R and IR Catalytic Domains

The sources of enzyme for these studies were E. coli expression vectors encoding fusion proteins between the kinase catalytic domains and glutathione S-transferase (GST). This expression system allows purification of the protein under nondenaturing conditions by absorption to glutathione-agarose, followed by elution with excess reduced glutathione (Smith and Johnson, 1988). Our laboratory has recently described the construction and characterization of such vectors for the nonreceptor tyrosine kinases v-Src and v-Abl (Garcia et al., 1993). (^2)The specific activities of these fusion proteins are comparable to that of the kinases purified from transformed cells (Garcia et al., 1993). In the present study the catalytic domains of IR and IGF-1R were purified to homogeneity using this system. The procaryotic expression system for the receptor tyrosine kinase domains developed here will permit more facile structure-function studies of the enzymes (for example, by the use of site-directed mutagenesis to probe substrate specificity).

Although the GST-IR and GST-IGF-1R fusion proteins were isolated in a soluble form, a substantial portion (approx75%) of the protein was lost as a pellet in the clarifying centrifugation step after the bacterial cells were sonicated. This loss might be due to the insolubility of the expressed protein or to coaggregation with bacterial membranes. Because of the low yield of soluble fusion protein (approx100 µg/liter of cells), we were unable to carry out the thrombin cleavage reaction (Smith and Johnson, 1988) to produce the catalytic domain in sufficient quantities for kinetic analyses. Consequently, we used the intact GST fusion proteins to test for phosphorylation of the IRS-1 peptide substrates. Tyrosine kinase activity was tested using the phosphocellulose paper assay. These results ( Table 2and Table 3) indicated that insulin and IGF-1 receptor catalytic domains, expressed in E. coli as described above, possess functional tyrosine kinase activity. The specific activities of the fusion proteins were similar to those reported for other recombinant tyrosine kinase catalytic domains (e.g. Herrera et al., 1988; Morgan et al., 1991; Garcia et al., 1993), and the specificities appear to be unaltered, as judged from comparison of the GST-IR protein to a partially purified preparation of IR holoreceptor toward synthetic peptides (see below). These observations show that the catalytic domain of IGF-1R, like that of insulin receptor (Herrera et al., 1988; Cobb et al., 1989) is active in the absence of its ligand-binding and transmembrane domains.





Divalent Cation Requirements for Insulin and IGF-1 Receptors

In a recent study of the cation dependence of the IR, IGF-1R, and a chimeric IGF-1R receptor containing the IR C-terminal 112 amino acids, it was demonstrated that the receptors had distinguishable preferences for Mn and Mg (Mothe et al., 1995). In particular, at either 10 or 50 mM Mg, the ligand-stimulated phosphorylation of an exogenous substrate by IR was increased by the addition of Mn. In contrast, the addition of Mn decreased the stimulatory effect of IGF-1 on IGF-1R kinase activity (Mothe et al., 1995). In those studies, the chimeric receptor resembled the IR at low concentrations of Mg and the IGF-1R at high concentrations of Mg (50 mM). To test whether the catalytic domains of IR and IGF-1R themselves possess intrinsic specificities for divalent cations, we tested the phosphorylation of Peptide Y727 (Table 1) by IR and IGF-1R under a variety of ionic conditions (Fig. 1). In all cases (for IR and for IGF-1R, and at low and high Mg concentrations), addition of 2 mM Mn was found to increase the phosphorylation of the exogenous peptide by the tyrosine kinases. Both receptors were found to be slightly more responsive to Mn at a lower concentration of Mg (Fig. 1). Additional Mn (4 mM) appeared to increase the catalytic efficiencies of both receptor kinases (data not shown). Thus, the two catalytic domains do not appear to have any intrinsic differences in their divalent cation preferences. The results for ligand-induced stimulation of holoreceptors (Mothe et al., 1995) may have been due to the presence of additional regions of IR and IGF-1R not included in this study, such as the ligand-binding domain or the C-terminal amino acids, which have been shown to play an important role in signal transmission (Mothe et al., 1995). The similarity in cation specificity observed here is consistent with results reported previously for partially purified preparations of IR and IGF-1R from rat liver cells (Sasaki et al., 1985).




Figure 1: Divalent cation specificity of insulin and IGF-1 receptor kinases. Enzyme reactions were carried out in 50 mM Tris-HCl (pH 7.4), and contained 1 mg/ml bovine serum albumin, 200 µM [-P]ATP (100-500 cpm/pmol), 1.0 mM Peptide Y727, and the indicated concentrations of MgCl(2) and MnCl(2). Results are given as mean ± S.D.



Phosphorylation of IRS-1 Peptides

Experiments with chimeric receptors in vivo (Lammers et al., 1989) and phosphorylation of synthetic tyrosine-containing polymers in vitro (Sahal et al., 1988) demonstrate a difference in substrate specificity between the insulin and IGF-1 receptors. Detailed knowledge about the relative substrate specificities of the two receptor kinases would be an important first step in the identification of their natural substrates. Both IR and IGF-1R are known to phosphorylate IRS-1 (Sun et al., 1991; Myers et al., 1993). Several tyrosine phosphorylation sites in IRS-1 are predicted to be within Tyr-Met-X-Met (YMXM) motifs, and synthetic peptides corresponding to these sequences are excellent substrates for IR in vitro (Shoelson et al., 1992). When phosphorylated, several of these motifs become specific binding sites for SH2-containing signaling molecules (Sun et al., 1993). Thus, differential phosphorylation of tyrosines within IRS-1 could account for the differences in signaling observed in intact cells. To test this notion, the substrate specificity of IGF-1R and IR was measured with a series of peptides derived from IRS-1, as shown in Table 1. These sequences correspond to major sites for IR phosphorylation in vivo, and include those sites which have been shown to bind SH2-containing proteins after phosphorylation. For each synthetic peptide, if sufficient basic residues were not present within the native sequence for absorption to phosphocellulose paper under the acidic conditions of the assay (Casnellie, 1991), additional lysine residues were added to the N terminus.

As shown in Table 2, all of the IRS-1 peptides served as good substrates for the catalytic domain of the IGF-1R kinase. Experiments were performed at saturating concentrations of ATP (200 µM) and Mg (10 mM) to arrive at values of K(m) and V(max) for the peptides. The IGF-1R catalytic domain exhibited distinct preferences for the IRS-1 peptides; these preferences tended to be dominated by K(m) rather than by V(max). K(m) values ranged from a low of 26 µM (Y895) to a high of 249 µM (Y628), whereas V(max) values fell between 0.5 and 1.6 nmol/min/mg (Table 2). These peptides are among the best reported in vitro substrates for the IGF-1 receptor tyrosine kinase to date. In terms of k/K(m), the most meaningful parameter for substrate specificity comparison (Fersht, 1985), the best substrate was Y895 (Table 2). When phosphorylated, the site surrounding Y895 in IRS-1 has been shown to be a binding site for Grb2 (Sun et al., 1993), a small adapter molecule that contains one SH2 domain and two SH3 domains. The poorest substrate of this series was Peptide Y987, with k/K(m) reduced approx14-fold from Peptide Y895.

With the exception of Y895 and Y1172, all of the peptides listed in Table 1have been tested as substrates for the insulin receptor tyrosine kinase (Shoelson et al., 1992). These results showed that the preferred sequence for phosphorylation was Y987, although for IR the peptides were all excellent substrates and only displayed a 2-fold range of k/K(m) (Shoelson et al., 1992). Peptides Y895, Y987, and Y1172 were therefore compared as substrates for the catalytic domain of the IR (Table 3). Peptide Y987 had the lowest value of K(m) (30 µM) and the highest value of k/K(m) (2.6 times 10^3M min) of these three peptides. These results contrasted with those for IGF-1R (Table 2), in which Y895 was preferred over Y987 and Y1172. The results obtained for IGF-1R and IR catalytic domains, along with those obtained previously for IR, are compared directly in terms of relative k/K(m) in Fig. 2. It can be seen from these data that the IGF-1R has a stricter substrate specificity for the IRS-1 phosphorylation sites, with Y895 being the best and Y628, Y987, and Y1172 being more poorly recognized. In contrast, the insulin receptor kinase preferentially phosphorylates peptides corresponding to IRS-1 sites Y727 and Y987. These differences in YMXM substrate specificity may also represent a difference in signaling potential between IR and IGF-1R.


Figure 2: Phosphorylation of IRS-1 peptides by IGF-1 and insulin receptors. In each case k/K values are normalized to 1.0 for the best substrate (for IGF-1R (&cjs2113;), Peptide Y895; for IR (&cjs2110;), Peptide Y987). For IGF-1R, k/K values are taken from Table 2. For insulin receptor, k/K values for Peptides Y895, Y987, and Y1172 are from Table 3. Values of k/K for the remaining peptides with insulin receptor are taken from Shoelson et al.(1992).



Phosphorylation by v-Src

It has recently been reported that IGF-1R exhibits an elevated level of tyrosine phosphorylation in cells expressing v-Src, even in the absence of stimulation by IGF-1 (Peterson et al., 1994). In these cells, phosphorylation of IGF-1R was correlated with increased tyrosine kinase activity of the receptor, as measured both by autophosphorylation and by phosphorylation of exogenous substrates. These studies suggest that IGF-1R is an in vivo substrate for v-Src. We tested whether the catalytic domains of IR and IGF-1R would be activated by treatment with purified v-Src. For these studies, IR and IGF-1R were incubated with Src and unlabeled ATP for 20 min and then reisolated by adsorption onto glutathione-agarose. Because the baculovirus vector used to express v-Src does not encode a GST fusion protein, glutathione-agarose adsorption served to remove Src from the reactions. Recovery of the IR and IGF-1R was quantitative under these conditions, as judged by comparisons of enzymatic activity with equivalent amounts of receptors which were not adsorbed onto glutathione-agarose (data not shown). The tyrosine kinase activities of the IR and IGF-1R were then measured by addition of kinase assay buffer, Peptide Y727, and [-P]ATP directly to the resin-bound enzymes. In these experiments, the activity of IGF-1R was elevated approximately 3.4-fold after treatment with v-Src, relative to the untreated control (Fig. 3). In contrast, the activity of the GST-IR protein was increased only by a factor of 1.2 (Fig. 3). In a control reaction with Src alone, no Src activity remained bound to the glutathione-agarose beads after washing (Fig. 3).


Figure 3: Activation of IGF-1R and insulin receptors by v-Src. GST fusions of receptor tyrosine kinases were incubated in the presence or absence of purified v-Src as indicated. After reisolating the receptor kinases, their activities were measured toward Peptide Y727 using the phosphocellulose paper assay. In some experiments Yersinia tyrosine phosphatase (PTPase) was added together with v-Src. The amount of Src kinase activity which nonspecifically associates with the glutathione-agarose beads is shown in the right-hand panel of the figure. Assays were carried out in triplicate and are given as mean ± S.D.



To confirm that activation of IGF-1R in the presence of Src depended on the tyrosine phosphorylation of the receptor, the reactions were also carried out in the presence of the Yersinia tyrosine phosphatase. After exposure to Src and the Yersinia phosphatase, IGF-1R and IR were isolated by adsorption onto glutathione-agarose and tested for tyrosine kinase activity toward the synthetic peptide. As shown in Fig. 3, treatment with the tyrosine-specific phosphatase reversed the activation by Src, indicating that the increased IGF-1R activity was due to increased tyrosine phosphorylation of the receptor. Thus, in an experimental system consisting of only the catalytic domains of the receptor tyrosine kinases, the ability of v-Src to activate IGF-1R was reproduced. The degree of activation seen here correlates well with the ligand-independent increase in kinase activity measured when IGF-1R was immunoprecipitated from Src-expressing cells (Peterson et al., 1994).


DISCUSSION

The insulin and IGF-1 receptors exhibit a large degree of similarity, both with respect to their enzymatic properties and to their structural organization. On the other hand, the biological responses elicited by the two receptors are different, suggesting that specific signaling pathways must exist. The IGF-1 receptor appears to be intrinsically more effective at stimulating DNA synthesis than the insulin receptor (Kahn, 1985; Rechler and Nissey, 1990; Adamo et al., 1992). Of particular interest are recent results which show that IGF-1 receptor is required for the establishment and maintenance of the transformed phenotype in vivo and in vitro. For example, when overexpressed in NIH3T3 cells, the IGF-1 receptor causes uncontrolled cell growth and neoplastic transformation (Kaleko et al., 1990). Identification of specific components of the signaling pathways would provide a major step forward in the understanding of IGF-I and insulin action. The experiments described here approach this problem by focusing on the in vitro tyrosine kinase activity of the isolated catalytic domains. The substrate specificities of the bacterial fusion proteins used in this study appear to be similar to those reported for intact receptors; for example, K(m) values for phosphorylation of several of the YMXM-containing substrates are nearly identical to those reported for a partially purified preparation of insulin receptor (Shoelson et al., 1992) ( Table 3and data not shown).

One signaling element that is common to both insulin and IGF-1 receptor pathways is the 185-kDa protein IRS-1. This protein becomes tyrosine phosphorylated in response to insulin or IGF-1 treatment, and subsequently associates with the phosphatidylinositol 3`-kinase and other SH2-containing proteins (Sun et al., 1993). Because of the large number of potential sites for tyrosine phosphorylation in IRS-1 (Sun et al., 1991), the possibility exists that different sites (or combinations of sites) are recognized and phosphorylated by the insulin and IGF-1 receptors, giving rise to different docking sites for downstream signaling molecules containing SH2 domains. Additionally or alternatively, individual SH2 domain-containing proteins might be expressed preferentially with one or the other receptor tyrosine kinase.

To test whether the sites of IRS-1 are recognized differentially by the two enzymes, we have tested a series of synthetic peptides which reproduce the major tyrosine phosphorylation sites on IRS-1. Interestingly, we observe differences in substrate specificity between the two enzymes in these studies ( Table 2and Table 3; summarized in Fig. 2). Whereas the insulin receptor displays a rather broad specificity, with Peptides Y727 and Y987 being the best substrates, IGF-1 receptor has a more restricted specificity and prefers Peptide Y895. While we cannot identify the precise amino acid determinants for phosphorylation by the two enzymes, it is interesting to note that substitutions at either methionine residue in YMXM motifs invariably leads to decreased catalytic efficiency for the insulin receptor, suggesting that the Met and Met residues play important roles in enzyme-substrate recognition (Shoelson et al., 1992). The IGF-1 receptor kinase appears to be less dependent on C-terminal methionine residues; Peptide Y895, which contains the sequence Tyr-Val-Asn-Ile, is the preferred site. These experiments demonstrate for the first time distinctions between the substrate specificities of the insulin and IGF-1 receptors using amino acid sequences that are physiologically relevant. The results are consistent with earlier studies on random copolymers of amino acids, which also showed different preferences for the two receptor kinases (Sahal et al., 1988).

These distinctions in specificity toward IRS-1 peptides in vitro may parallel a difference in signaling by IGF-1 and insulin receptors through IRS-1. Recently it has been shown that a 262-amino acid portion of IRS-1 (residues 516-777), which contains five potential YMXM or YXXM phosphorylation sites, is recognized similarly by insulin and IGF-1 receptors (K(m) = 6.8 and 9.9 µM, respectively) (Siemeister et al., 1995). However, Tyr-895, which lies outside of this region of IRS-1, may be a determinant for downstream signaling that is favored by IGF-1 receptor. After phosphorylation, the Tyr-895 site in IRS-1 constitutes a binding site for the Grb2 adapter protein (Sun et al., 1993). Genetic and biochemical evidence suggests that Grb2 is an upstream regulator of the GTP exchange protein mSOS, which stimulates the formation of an active p21-GTP complex (Egan et al., 1993; Gale et al., 1993; Olivier et al., 1993; Rozakis-Adcock et al., 1993). Thus, promotion of stable binding between IRS-1 and Grb2 may play a role in the mitogenic signaling of IGF-1. On the other hand, alternate pathways to IRS-1 may exist for insulin or IGF-1 signaling, as suggested by experiments with transgenic IRS-1 knockout mice (Araki et al., 1994; Tamemoto et al., 1994). In the case of insulin receptor, it has recently been shown that Grb2 associates rapidly and transiently with IRS-1 after insulin treatment, but that Shc plays a more important role than IRS-1 in the binding of Grb2 and formation of p21-GTP (Sasaoka et al., 1994).

We also show that the insulin and IGF-1 receptors differ with regard to their potential for activation by v-Src (Fig. 3). It has been shown recently that the IGF-1 receptor becomes tyrosine phosphorylated in cells expressing v-Src, and that the in vivo increase in phosphorylation parallels an increased in vitro tyrosine kinase activity of the IGF-1 receptor (Peterson et al., 1994). In these studies it was not shown whether IGF-1 receptor acted as a direct substrate for v-Src in vitro, or where on the IGF-1 receptor the site(s) for Src phosphorylation occurred. Under the in vitro conditions reported here, the kinase activity of the IGF-1 receptor catalytic domain was stimulated approximately 3.4-fold by v-Src, whereas the activity of insulin receptor showed only a modest increase after treatment with v-Src under identical conditions. Activation was due to increased tyrosine phosphorylation, as demonstrated by reversal of the effect by a tyrosine-specific phosphatase. In these experiments Src may catalyze the direct phosphorylation of IGF-1R catalytic domain, or act indirectly, by promoting receptor autophosphorylation. We favor the former explanation since it has been shown that v-Src can cause tyrosine phosphorylation of an inactive mutant of the IGF-1 receptor in vivo (Peterson et al., 1994). Our in vitro experiments indicate that the IGF-1 receptor has the potential to act as a direct substrate for v-Src, and that at least one target for Src phosphorylation may be present in the catalytic domain of IGF-1R itself. The level of activation observed (approx3.4-fold) is similar to the level of increased IGF-1 receptor kinase activity seen in vivo (approx4-fold). Activation of IGF-1 receptor (or other receptor tyrosine kinases) could be a regulatory mechanism by which v-Src amplifies its signaling potential. In the case of IGF-1 receptor, this may be particularly important because of the role of the receptor in stimulating mitogenesis and because of its oncogenic potential (Kaleko et al., 1990). Overexpression of IGF-1 receptor in NIH3T3 cells leads to ligand-dependent morphological transformation and colony growth in soft agar, and cells overexpressing IGF-1R cause the formation of tumors when introduced into nude mice (Kaleko et al., 1990).

In conclusion, we have demonstrated distinctions between the tyrosine kinase catalytic domains of the IGF-1 receptor and insulin receptor. Studies with chimeric receptors indicate that the biological specificity of these two polypeptide hormones can be attributed to the cytoplasmic portions of their beta subunits. For example, a chimeric receptor composed of the extracellular domain of the insulin receptor and the cytoplasmic portion of the IGF-1 receptor behaves similarly to the wild-type IGF-1 receptor (Lammers et al., 1989). This implies that a detailed knowledge of receptor kinase substrate specificity may shed light on the different downstream signaling pathways triggered by insulin and IGF-1.


FOOTNOTES

*
This work was supported by a grant from the National Institutes of Health CA58530 (to W. T. M.), and by the Center for Biotechnology at Stony Brook, funded by the NY State Science and Technology Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Dept. of Physiology and Biophysics, Basic Science Tower T-6, School of Medicine, SUNY at Stony Brook, Stony Brook, NY 11794-8661. Tel.: 516-444-3533; Fax: 516-444-3432.

(^1)
The abbreviations used are: IGF-1, insulin-like growth factor 1; IRS-1, insulin receptor substrate-1; IR, insulin receptor; Grb2, growth factor receptor bound 2; GST, glutathione S-transferase.

(^2)
B. Xu and W. T. Miller, submitted for publication.


ACKNOWLEDGEMENTS

We thank Dr. Jonathan Whittaker (Stony Brook) for cDNAs encoding the human insulin and IGF-1 receptors and for critical review of the manuscript, and Dr. Zhong-Yin Zhang (Albert Einstein) for providing a sample of purified Yersinia tyrosine phosphatase.


REFERENCES

  1. Adamo, M., Roberts, C. T., and LeRoith, D. (1992) Biofactors 3, 151-157 [Medline] [Order article via Infotrieve]
  2. Araki, E., Lipes, M. A., Patti, M.-E., Bruning, J. C., Haag, B., Johnson, R. S., and Kahn, C. R. (1994) Nature 372, 186-190 [CrossRef][Medline] [Order article via Infotrieve]
  3. Backer, J. M., Myers, M. G., Jr., Shoelson, S. E., Chin, D. J., Sun, X. J., Miralpeix, M., Hu, P., Margolis, B., Skolnik, E. Y., Schlessinger, J., and White, M. F. (1992) EMBO J. 11, 3469-3479 [Abstract]
  4. Baserga, R. (1995) Cancer Res. 55, 249-252 [Abstract]
  5. Casnellie, J. E. (1991) Methods Enzymol. 200, 115-120 [Medline] [Order article via Infotrieve]
  6. Chou, C. K., Dull, T. J., Russell, D. S., Gherzi, R., Lebwohl, D., Ullrich, A., and Rosen, O. M. (1987) J. Biol. Chem. 262, 1842-1847 [Abstract/Free Full Text]
  7. Cobb, M. H., Sang, B.-C., Gonzalez, R., Goldsmith, E., and Ellis, L. (1989) J. Biol. Chem. 264, 18701-18706 [Abstract/Free Full Text]
  8. Ebina, Y., Araki, E., Taira, M., Shimada, F., Mori, M., Craik, C. S., Siddle, K., Pierce, S. B., Roth, R. A., and Rutter, W. J. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 704-708 [Abstract]
  9. Egan, S. E., Giddings, B. W., Brooks, M. W., Buday, L., Sizeland, A. M., and Weinberg, R. A. (1993) Nature 363, 45-51 [CrossRef][Medline] [Order article via Infotrieve]
  10. Fersht, A. (1985) Enzyme Structure and Mechanism, 2nd Ed., W. H. Freeman and Co., San Francisco, CA
  11. Gale, N. W., Kaplan, S., Lowenstein, E. J., Schlessinger, J., and Bar-Sagi, D. (1993) Nature 363, 88-92 [CrossRef][Medline] [Order article via Infotrieve]
  12. Garcia, P., Shoelson, S. E., George, S. T., Hinds, D. A., Goldberg, A. R., and Miller, W. T. (1993) J. Biol. Chem. 268, 25146-25151 [Abstract/Free Full Text]
  13. Giorgetti, S., Ballotti, R., Kowalski-Chauvel, A., Tartare, S., and Van Obberghen, E. (1993) J. Biol. Chem. 268, 7358-7364 [Abstract/Free Full Text]
  14. Hanks, S. K., Quinn, A. M., and Hunter, T. (1988) Science 241, 42-52 [Medline] [Order article via Infotrieve]
  15. Herrera, R., Lebwohl, D., de Herreros, A. G., Kallen, R. G., and Rosen, O. M. (1988) J. Biol. Chem. 263, 5560-5568 [Abstract/Free Full Text]
  16. Kahn, C. R. (1985) Annu. Rev. Med. 36, 429-451 [CrossRef][Medline] [Order article via Infotrieve]
  17. Kaleko, M., Rutter, W. J., and Miller, A. D. (1990) Mol. Cell. Biol. 10, 837-841 [Medline] [Order article via Infotrieve]
  18. Kato, H., Faria, T. N., Stannard, B., Roberts, C. T., Jr., and LeRoith, D. (1993) J. Biol. Chem. 268, 2655-2661 [Abstract/Free Full Text]
  19. Lammers, R., Gray, A., Schlessinger, J., and Ullrich, A. (1989) EMBO J. 8, 1369-1375 [Abstract]
  20. Morgan, D. O., Kaplan, J. M., Bishop, J. M., and Varmus, H. E. (1991) Methods Enzymol. 200, 645-660 [Medline] [Order article via Infotrieve]
  21. Mothe, I., Tartare, S., Kowalski-Chauvel, A., Kaliman, P., Van Obberghen, E., and Ballotti, R. (1995) Eur. J. Biochem. 228, 842-848 [Abstract]
  22. Myers, M. G., Jr., Sun, X. J., Cheatham, B., Jachna, B. R., Glasheen, E. M., Backer, J. M., and White, M. F. (1993) Endocrinology 132, 1421-1430 [Abstract]
  23. Olivier, J. P., Raabe, T., Henkemeyer, M., Dickson, B., Mbamalu, G., Margolis, B., Schlessinger, J., Hafen, E., and Pawson, T. (1993) Cell 73, 179-191 [Medline] [Order article via Infotrieve]
  24. Peterson, J. E., Jelinek, T., Kaleko, M., Siddle, K., and Weber, M. J. (1994) J. Biol. Chem. 269, 27315-27321 [Abstract/Free Full Text]
  25. Rechler, M. M., and Nissley, S. P. (1990) in Handbook of Experimental Pharmacology: Polypeptide Growth Factors and Their Receptors I (Sporn, M. A., and Roberts, A. B., eds) Vol. 95, pp. 263-367, Springer-Verlag, Berlin/Heidelberg
  26. Rozakis-Adcock, M., Fernley, R., Wade, J., Pawson, T., and Bowtell, D. (1993) Nature 363, 83-84 [CrossRef][Medline] [Order article via Infotrieve]
  27. Sahal, D., Ramachandran, J., and Fujita-Yamaguchi, Y. (1988) Arch. Biochem. Biophys. 260, 416-426 [Medline] [Order article via Infotrieve]
  28. Sasaki, N., Rees-Jones, R. W., Zick, Y., Nissley, S. P., and Rechler, M. M. (1985) J. Biol. Chem. 260, 9793-9804 [Abstract/Free Full Text]
  29. Sasaoka, T., Draznin, B., Leitner, J. W., Langlois, W. J., and Olefsky, J. M. (1994) J. Biol. Chem. 269, 10734-10738 [Abstract/Free Full Text]
  30. Shoelson, S. E., Chatterjee, S., Chaudhuri, M., and White, M. F. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2027-2031 [Abstract]
  31. Siemeister, G., Al-Hasani, H., Klein, H. W., Kellner, S., Streicher, R., Krone, W., and Müller-Wieland, D. (1995) J. Biol. Chem. 270, 4870-4874 [Abstract/Free Full Text]
  32. Smith, D. B., and Johnson, K. S. (1988) Gene (Amst.) 67, 31-40 [CrossRef][Medline] [Order article via Infotrieve]
  33. Stewart, J. M., and Young, J. D. (1984) Solid Phase Peptide Synthesis, 2nd Ed., Pierce Chemical Co., Rockford, IL
  34. Sun, X. J., Rothenberg, P., Kahn, C. R., Backer, J. M., Araki, E., Wilden, P. A., Cahill, D. A., Goldstein, B. J., and White, M. F. (1991) Nature 352, 73-77 [CrossRef][Medline] [Order article via Infotrieve]
  35. Sun, X. J., Crimmins, D. L., Myers, M. G., Jr., Miralpeix, M., and White, M. F. (1993) Mol. Cell. Biol. 13, 7418-7428 [Abstract]
  36. Tamemoto, H., Kadowaki, T., Tobe, K., Yagi, T., Sakura, H., Hayakawa, T., Terauchi, Y., Ueki, K., Kaburagi, Y., Satoh, S., Sekihara, H., Yoshioka, S., Horikoshi, H., Faruta, Y., Ikawa, Y., Kasuga, M., Yazaki, Y., and Aizawa, S. (1994) Nature 372, 182-186 [CrossRef][Medline] [Order article via Infotrieve]
  37. Ullrich, A., Gray, A., Tam, A. W., Yang-Feng, T., Tsubokawa, M., Collins, C., Henzel, W., LeBon, T., Kathuria, S., Chen, E., Jacobs, S., Francke, U., Ramachandran, J., and Fujita-Yamaguchi, Y. (1986) EMBO J. 5, 2503-2512 [Abstract]
  38. Yarden, Y., and Ullrich, A. (1988) Annu. Rev. Biochem. 57, 443-478 [CrossRef][Medline] [Order article via Infotrieve]
  39. Zhang, Z.-Y., Clemens, J. C., Schubert, H. L., Stuckey, J. A., Fischer, M. W. F., Hume, D. M., Saper, M. A., and Dixon, J. E. (1992) J. Biol. Chem. 267, 23759-23766 [Abstract/Free Full Text]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.